Clinical Trials · NCT07232719
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Eli Lilly and Company
- Enrollment
- 250
- Start date
- Nov 2025
- Locations
- 31 sites, United States, United Kingdom
- Primary endpoint
- Percent Change from Baseline in Body Weight